Anchor Therapeutics collaborates with OMJPI to develop GPCR targeted therapeutic compounds

Download PDF Copy

Sep 9 2010

Anchor Therapeutics today announced that it has entered into a collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) with the goal of developing G protein coupled receptor (GPCR)-targeted therapeutic compounds utilizing Anchor's proprietary pepducin technology.

“We are excited about enhancing our pepducin drug development platform and pipeline of GPCR-targeted opportunities and look forward to working with OMJPI to discover new treatment options for patients”

Under the agreement, Anchor and OMJPI will work jointly to discover and optimize preclinical development candidates against GPCR targets in oncology and metabolic disorders, including Anchor's program targeting gpr39, a GPCR involved in metabolic diseases. OMJPI will assume responsibility for development and commercialization. Anchor will receive an upfront payment and research support and could be eligible for development and regulatory milestone payments up to $480 million.

"We are excited about enhancing our pepducin drug development platform and pipeline of GPCR-targeted opportunities and look forward to working with OMJPI to discover new treatment options for patients," said Frederick Jones, M.D., President and CEO of Anchor.

Source:

: Anchor Therapeutics

Posted in:

Comments (0)

Download PDF Copy

Suggested Reading

Once-monthly obesity injection shows double-digit weight loss in major clinical trial

Older adults reveal what makes or breaks a shift to plant-based protein

Lasting COVID-19 vulnerability in childhood cancer survivors

High protein diet linked to increased risk of cancer-associated venous thromboembolism

Piezo1 identified as key trigger for tension driven skin expansion

New nanobody-liposome combo stops lung cancer growth and delivers targeted chemotherapy

Eating more animal protein may slightly lower cancer mortality

Synthetic Biology and the Pursuit of Living Diagnostics and Therapeutics

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.